(Q43265626)

17 November 2017

Neuroprotection in Parkinson's disease: love story or mission impossible? (English)

1 reference

17 November 2017

1 reference

Gurutz J Linazasoro

1

1 reference

17 November 2017

1 May 2002

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

17 November 2017

1 reference

17 November 2017

2

1 reference

17 November 2017

3

1 reference

17 November 2017

403-416

1 reference

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

17 November 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Etiology and pathogenesis of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Alpha-synuclein and neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

A new link between pesticides and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Late-onset neurodegenerative diseases--the role of protein insolubility

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Aggresomes, inclusion bodies and protein aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Proteasomal function is impaired in substantia nigra in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Mitochondrial complex I deficiency in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

A one-hit model of cell death in inherited neuronal degenerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Parkinson disease in twins: an etiologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Complete genomic screen in Parkinson disease: evidence for multiple genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Neurodegeneration: a failure of neuroregeneration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Mitochondria and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Apoptosis in neurodegenerative diseases: the role of mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Science, medicine, and the future: Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Ageing and Parkinson's disease: substantia nigra regional selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

The heterogeneity of Parkinson's disease: clinical and prognostic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Assessing the integrity of the dopamine system in Parkinson's disease: how best to do it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Future of neuroprotection in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Selegiline and mortality in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Alternative excitotoxic hypotheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Neuroimmunophilins: novel neuroprotective and neuroregenerative targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

21 January 2018

Caspases: enemies within

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Multiple antioxidants in the prevention and treatment of neurodegenerative disease: analysis of biologic rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Mutant protein in Huntington disease is resistant to proteolysis in affected brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Pharmacological chaperones: a new twist on receptor folding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

Familial Aggregation of Parkinson's Disease in Iceland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.403

21 January 2018

Identifiers

DOI

10.1586/14737175.2.3.403

1 reference

17 November 2017

1 reference

PubMed ID

19810872